A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models - PubMed
12 hours ago
- #drug-repurposing
- #antiviral
- #enterovirus
- Enteroviruses cause diseases like HFMD and severe neurological issues in children.
- Vaccines lack cross-protection across enterovirus serotypes, necessitating broad-spectrum drugs.
- The viral 3C protease (3Cpro) is a key therapeutic target.
- Enterovirus 3Cpro shares features with SARS-CoV-2 Mpro, enabling inhibitor repurposing.
- Bofutrelvir, a SARS-CoV-2 Mpro inhibitor, shows nanomolar activity against multiple enteroviruses.
- Bofutrelvir reduces viral loads and symptoms in EV71-infected neonatal mice.
- Oral bofutrelvir is effective in EV71 and CA16 mouse models.
- Crystallography confirms bofutrelvir binds to EV71 3Cpro's conserved cleft.
- Bofutrelvir is a promising repurposed broad-spectrum antiviral for enteroviruses.